Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...
Allogene Therapeutics is a clinical stage biote...
BioClonetics Immunotherapeutics is a biotechnology company with a proprietary meth...
BioClonetics Immunotherapeutics is a biotechnol...
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed st...
Momenta Pharmaceuticals is a biotechnology comp...
BioTelemetry, Inc. is the leading remote medical technology company focused on the...
BioTelemetry, Inc. is the leading remote medica...
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers...
At Biogen, our mission is clear: we are pioneer...
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonan...
IRADIMED CORPORATION is a leader in the develop...
An emerging leader in the specialty pharmaceuticals industry, ANI Pharmaceuticals ...
An emerging leader in the specialty pharmaceuti...
Join the National Investor Network and get the latest information with your interests in mind.